Limitations of urine drug-screening (UDS) by immunoassay include false-positive results. Pantoprazole, a proton-pump inhibitor (PPI), is reported to cause false-positive results for THC on UDS. The objective of this study was to determine if oral PPIs cause false-positive THC results using the THC One Step Marijuana Test Strip. Eligible healthy volunteers completed a 5-day course of a PPI followed by urine testing using the THC One Step Marijuana Test Strip. Phase one included 3 subjects taking pantoprazole 40 mg once daily for 5 days. On day 5, urine specimens underwent THC screening. Phase two included 9 subjects randomized to 5-day supply of once-daily oral esomeprazole 20 mg, lansoprazole 15 mg, or omeprazole 20 mg. All study methods and testing mirrored those in phase one. All 12 subjects completed the study protocol. All urine samples collected on day 5 were negative for THC in all subjects. Our results demonstrate that oral PPIs did not cause a false-positive THC using the THC One Step Marijuana Test Strip. Limitations include small sample size, use of a single commercial immunoassay, and inability to confirm medication compliance. Further, large-scale research using other commercial urine immunoassays is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15563650.2019.1662917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sensitivity, specificity, and discordance with self-report of nail sample testing for alcohol and cannabis.
Drug Alcohol Depend
August 2024
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA; VA Connecticut Healthcare System, West Haven, CT 06516, USA.
Background: Nails accumulate the alcohol metabolite, ethyl glucuronide (ETG), and the cannabis metabolite, carboxy- delta-9-THC over 3-6 months. Few studies have examined nail toxicology testing's sensitivity and specificity and the agreement between nail testing and self-reported alcohol and marijuana use.
Methods: In an ongoing clinical trial, 1101 veterans completed initial telephone questionnaires and were then asked to mail nail clippings for substance use analysis.
Appearance of hexahydrocannabinols as recreational drugs and implications for cannabis drug testing - focus on HHC, HHC-P, HHC-O and HHC-H.
Scand J Clin Lab Invest
April 2024
Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
This study investigated the effects of hexahydrocannabinol (HHC) and other unclassified cannabinoids, which were recently introduced to the recreational drug market, on cannabis drug testing in urine and oral fluid samples. After the appearance of HHC in Sweden in 2022, the number of posts about HHC on an online drug discussion forum increased significantly in the spring of 2023, indicating increased interest and use. In parallel, the frequency of false positive screening tests for tetrahydrocannabinol (THC) in oral fluid, and for its carboxy metabolite (THC-COOH) in urine, rose from <2% to >10%.
View Article and Find Full Text PDFComplexity of Translating Analytics to Recent Cannabis Use and Impairment.
J AOAC Int
May 2024
RCU Labs, Inc., 408 Sunrise Ave, Roseville, CA 95661-4123, United States.
While current analytical methodologies can readily identify cannabis use, definitively establishing recent use within the impairment window has proven to be far more complex, requiring a new approach. Recent studies have shown no direct relationship between impairment and Δ9-tetra-hydrocannabinol (Δ9-THC) concentrations in blood or saliva, making legal "per se" Δ9-THC limits scientifically unjustified. Current methods that focus on Δ9-THC and/or metabolite concentrations in blood, saliva, urine, or exhaled breath can lead to false-positive results for recent use due to the persistence of Δ9-THC well outside of the typical 3-4 h window of potential impairment following cannabis inhalation.
View Article and Find Full Text PDF∆8-THC-COOH cross-reactivity with cannabinoid immunoassay kits and interference in chromatographic testing methods.
J Anal Toxicol
September 2023
Division of Workplace Programs, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD 20857, USA.
Because of structural similarities, the presence of 11-Nor-9-carboxy-∆8-tetrahydrocannabinol (∆8-THC-COOH) in a urine specimen might interfere with testing for 11-Nor-9-carboxy-∆9-tetrahydrocannabinol (∆9-THC-COOH). A set of samples containing ∆8-THC-COOH with concentrations ranging from 10 to 120 ng/mL were tested at cut-offs of 20, 50 and 100 ng/mL using cannabinoid immunoassay reagents from three different manufacturers. Cross-reactivities ranged from 87% to 112% for ∆8-THC-COOH at the cut-off of 50 ng/mL for the three different platforms.
View Article and Find Full Text PDFChemical identification and optimization of the 4-aminophenol colorimetric test for the differentiation between hemp-type and marijuana-type cannabis plant samples.
J Forensic Sci
July 2023
Department of Chemistry and Biochemistry and Center for Advanced Research in Forensic Science, Florida International University, Miami, Florida, USA.
The 4- Aminophenol (4-AP) colorimetric test is a fast, easy-to-use, and cost-effective presumptive assay of cannabis plant material producing different chromophores with THC-rich cannabis (blue color) and with CBD-rich cannabis (pink color). The main drawback of the 4-AP test is a brief observation window where the color rapidly changes to black, limiting the utility of the test. We now report for the first time, the identification of the product chromophores between 4-AP and CBD/THC as well as propose an explanation and a solution for the color degradation of the chromophores.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!